Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 12, 2002, Pages 3907-3916

  Shulman, Nancy ^a,f   Zolopa, Andrew ^a   Havlir, Diane ^b   Hsu, Ann ^c   Renz, Cheryl ^c   Boller, Sheila ^c   Jiang, Ping ^c   Rode, Richard ^c   Gallant, Joel ^d   Race, Elizabeth ^e   Kempf, Dale J ^c   Sun, Eugene ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ABBOTT LABORATORIES   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; RITONAVIR; PROTEINASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG MIXTURE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHENOTYPE; PRIORITY JOURNAL; VIREMIA; VIRTUAL INHIBITORY QUOTIENT; VIRUS LOAD; VIRUS RESISTANCE; GENETICS; PROSPECTIVE STUDY; STATISTICAL MODEL;

ADULT; AREA UNDER CURVE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; LOGISTIC MODELS; MALE; PHENOTYPE; PROSPECTIVE STUDIES; RITONAVIR;

EID: 0036895440     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.12.3907-3916.2002     Document Type: Article

References (19)

1. Acosta, E. P., K. Henry, L. Baken, L. M. Page, and C. Fletcher. 1999 Indinavir concentrations and antiviral effect. Pharmacotherapy 19:708-712.
2. Burger, D. M., R. M. W. Hoetelmans, P. W. H. Hugen, J. W. Mulder, P. L. Meenhorst, P. P. Koopmans, K. Brinkman, M. Keuter, W. Dolmans, and Y. A. Hekster. 1998 Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir. Ther. 3:215-220.
3. DeGruttola, V., L. Dix, R. D'Aquila, D. Holder, A. Phillips, M. Ait-Khaled, J. Baxter, P. Clevenbergh, S. Hammer, R. Harrigan, D. Katzenstein, R. Lanier, M. Miller, M. Para, S. Yerly, A. Zolopa, J. Murray, A. Patrick, V. Miller, S. Castillo, L. Pedneault, and J. Mellors. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Reanalysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther. 5:41-48.
4. Dieleman, J. P., I. C. Guyssens, M. E. van der Ende, S. de Marie, and D. M. Burger. 1999 Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 13:473-478.
5. Dumon, C., C. Solas, I. Thuret, H. Chambost, B. Lacarelle, G. Michel, and A. Durand. 2000 Relationship between efficacy, tolerance, and plasma drug concentration of ritonavir in children with advanced HIV infection. Ther. Drug Monit. 22:402-408.
6. Durant, J., P. Clevenbergh, R. Garraffo, P. Halfon, S. Icard, P. Del Giudice, N. Montagne, J. M. Schapiro, and P. Dellamonica. 2000 Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study. AIDS 14:1333-1339.
7. Ellner, P. D., and H. C. Neu 1981 The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. JAMA 246:1575-1578.
8. Flexner, C. 2000 Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits. Annu. Rev. Pharmacol. Toxicol. 40:649-674.
9. Haas, D. W., E. Arathoon, M. A. Thompson, R. de Jesus Pedro, J. E. Gallant, D. E. Uip, J. Currier, L. M. Noriega, D. S. Lewi, P. Uribe, L. Benetucci, P. Cahn, D. Paar, A. C. White, Jr., A. C. Collier, C. H. Ramirez-Ronda, C. Harvey, M. O. Chung, D. Mehrotra, J. Chodakewitz, and B. Y. Nguyen. 2000 Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. AIDS 14:1973-1978.
10. Hertogs, K., M. P. de Bethune, V. Miller, T. Ivens, P. Schel, A. Van Cauwenberge, C. Van Den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
11. Hsu, A., G. R. Granneman, G. Cao, L. Carothers, A. Japour, T. El-Shourbagy, S. Dennis, J. Berg, K. Erdman, J. M. Leonard, and E. Sun. 1998 Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob. Agents Chemother. 42:2784-2791.
12. Kakuda, T. N., L. M. Page, P. L. Anderson, K. Henry, T. W. Schacker, F. S. Rhame, E. P. Acosta, R. C. Brundage, and C. V. Fletcher. 2001 Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrob. Agents Chemother. 45:236-242.
13. Kempf, D. J., K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, B. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997 Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660.
14. Lalezari, J. 1998 Selecting the optimum dose for a new soft gelatin capsule formulation of saquinavir. NV15107 Study Group. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 19:195-197.
15. Lorenzi, P., S. Yerly, K. Abderrakim, M. Fathi, O. T. Rutschmann, J. von Overbeck, D. Leduc, L. Perrin, B. Hirschel, et al. 1997 Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. AIDS 11:F95-F99.
16. Molla, A., S. Vasavanonda, G. Kumar, H. L. Sham, M. Johnson, B. Grabowski, J. F. Denissen, W. Kohlbrenner, J. J. Plattner, J. M. Leonard, D. W. Norbeck, and D. J. Kemp. 1998 Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 250:255-262.
17. Slain, D., A. Pakyz, D. S. Israel, S. Monroe, and R. E. Polk. 2000 Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 20:898-907.
18. Winters, M. A., J. M. Schapiro, J. Lawrence, and T. C. Merigan. 1998 Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long term saquinavir treatment. J. Virol. 72:5303-5306.
19. Zhou, X. J., D. V. Havlir, D. D. Richman, E. P. Acosta, M. Hirsch, A. C. Collier, P. Tebas, and J. P. Sommadossi. 2000 Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS 14:2869-2876.